Pure Global AI
NCT06217523Not yet recruiting

Personalised Hyperlipidaemia Therapies Guided by Pharmacogenomics

Designing Therapy to Suit You - Personalised Hyperlipidaemia Therapies Guided by Pharmacogenomics (DTSY Lipid PGx): A Randomised Controlled Trial
National University of SingaporeClinicalTrials.govother
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Drug/Device/Intervention
Pharmacogenomics-directed Hyperlipidaemia Management
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
National University of Singapore
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 01, 2025
Enrollment
700 participants
Primary outcome

Changes in LDL-C, HDL-C, Total cholesterol, and Triglycerides,Change in creatine kinase,Incidence of myopathy complaints

Summary

This trial aims to evaluate the impact of clinical pharmacists' pharmacogenomics-guided
 choice and statin titration for managing hyperlipidaemia.
 
 The central hypotheses of this trial are (1) clinical pharmacists' pharmacogenomics-guided
 choice and titration of statins will lead to a more significant reduction in LDL-c; (2) lower
 incidence of myopathies with the use of statins for hyperlipidaemia management over 12 months
 compared to usual care by doctors alone. Active follow-up and titration should occur over the
 first six months. However, the participants will be followed up to 12 months to confirm the
 sustained LDL level attainment.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06217523
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06217523 through Pure Global AI's free database. This phase not specified trial is sponsored by National University of Singapore and is currently Not yet recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 700 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.